PGEN / Precigen, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

LOAN AGREEMENT Dated as of September 3, 2025 PRECIGEN, INC. (as Borrower and a Credit Party), THE GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME (as additional Credit Parties), BIOPHARMA CREDIT PLC (as Collateral Agent), BPCR

Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE DESIGNATED AS “[***]”. LOAN AGREEMENT Dated as of September 3, 2025 among PRECIGEN, INC. (as Borrower and a Credit Party), THE GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2025 PRECIGEN, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2025 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File N

Precigen Announces Up to $125 Million Non-Dilutive Financing

Exhibit 99.1 Precigen Announces Up to $125 Million Non-Dilutive Financing $100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international markets and the pursuit of pediatric and other HPV-related indications GERMANTOWN, MD, September 3, 2025 - Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company sp

CALCULATION OF FILING FEE TABLES PRECIGEN, INC. Table 1: Newly Registered and Carry Forward Securities

Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 PRECIGEN, INC. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Series A Convertible P

As filed with the Securities and Exchange Commission on August 19, 2025

As filed with the Securities and Exchange Commission on August 19, 2025 Registration No.

US FDA Approval of PAPZIMEOS August 18, 2025 2 Forward-looking Statement This presentation contains “forward-looking” statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-look

Exhibit 99.1 US FDA Approval of PAPZIMEOS August 18, 2025 2 Forward-looking Statement This presentation contains “forward-looking” statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “exp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 PRECIGEN, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Num

COMMERCIAL SUPPLY AGREEMENT (Gene Therapy - PRGN-2012)

Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE DESIGNATED AS “[***]”. EXECUTION VERSION CONFIDENTIAL COMMERCIAL SUPPLY AGREEMENT (Gene Therapy - PRGN-2012) This Commercial Supply Agreement is made as of the date of the last sig

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Precigen, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Num

to the Amended and Restated

pgen-20250630xexx31 ARTICLES OF AMENDMENT OF PRECIGEN, INC. The undersigned, on behalf of the corporation set forth below, pursuant to Title 13.1, Chapter 9, Article 11 of the Code of Virginia, states as follows: 1. The name of the corporation is Precigen, Inc. (the “Corporation”). 2. The amended and restated articles of incorporation of the Corporation (the “Articles”) are hereby amended by delet

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 Precigen, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  ☐

Precigen, Inc. and Subsidiaries Consolidated Balance Sheets

Exhibit 99.1 Precigen Reports First Quarter 2025 Financial Results and Business Updates · PRGN-2012 has the potential to be the first- and best-in-class treatment for RRP · Company's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025 · RRP is a rare, debilitating chronic disease with approximately 27,00

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a party other than the Registrant  ☐ Check the appropriate box: ☒ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rul

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file num

List of Subsidiaries of Precigen, Inc.

Exhibit 21.1 List of Subsidiaries of Precigen, Inc. Domestic Exemplar Genetics, LLC Iowa Precigen ActoBio, Inc. Delaware Precigen ActoBio Holdings, Inc. Delaware International ActoBio Laboratories Belgium BVBA (besloten vennootschap met beperkte aansprakelijkheid) Belgium Intrexon ActoBiotics NV (naamloze vennootschap) Belgium

Insider Trading Policy

1 Nov. 2020 PRECIGEN, INC. INSIDER TRADING POLICY (Effective November 8, 2020) I. PURPOSE This Insider Trading Policy (the “Policy”) provides general guidelines with respect to transactions in the securities of Precigen, Inc. (the “Company”) and the handling of confidential information about the Company (including all of its subsidiaries and affiliates) and the companies with which the Company doe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36042 PRECI

Product Commercialization Agreement

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2025 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numb

Precigen, Inc. and Subsidiaries Consolidated Balance Sheets

Exhibit 99.1 Precigen Reports Full Year 2024 Financial Results and Business Updates · FDA granted priority review to Company’s BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date for August 27, 2025 · Results from pivotal clinical study of PRGN-2012 were published in The Lancet Respiratory Medicine · PRGN-2012 treatment demonstra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 Precigen, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Nu

Securities Purchase Agreement, dated December 27, 2024 between Precigen Inc. and the Investors party thereto

Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT Dated December 27, 2024 between PRECIGEN, INC. and THE INVESTORS PARTY HERETO TABLE OF CONTENTS Page Recitals 1 Article I Purchase; Closing 1.1 Purchase 1 1.2 Closing 1 1.3 Interpretation 3 Article II Representations and Warranties 2.1 Disclosure 3 2.2 Representations and Warranties of the Company 5 2.3 Representations and Warranties of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2024 Precigen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2024 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File N

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis – PRGN-2012 has the potential to be the first FDA-approved therapeutic for the treatm

EXHIBIT 99.2 Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis – PRGN-2012 has the potential to be the first FDA-approved therapeutic for the treatment of adults with RRP, a rare and devastating chronic disease for which the current standard-of-care is repeated surgeries – – PRGN-2012

Articles of Amendment to the Amended and Restated Articles of Incorporation

Exhibit 3.1 ARTICLES OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION OF PRECIGEN, INC. 1. Name of Corporation. The name of the Corporation is Precigen, Inc. 2. Text of Amendment. Article III of the Corporation’s Amended and Restated Articles of Incorporation (the “Articles of Incorporation”) shall be amended to add Article III.D. as set forth in Appendix A attached hereto, stati

Form of Common Stock Purchase Warrant

Exhibit 10.3 FORM OF COMMON STOCK PURCHASE WARRANT THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF EXCEPT WHILE A REGISTRATION STATEMENT RELATING THERETO IS IN EFFECT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Exhibit 99.1 Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock GERMANTOWN, Md., December 27, 2024 /PRNewswire/ - Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that it has entered into a securities purchase agreement for the sa

Joint Filing Agreement

Exhibit 4 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Precigen, Inc.

Registration Rights Agreement, dated December 30, 2024 between Precigen Inc. and the Investors party theret

Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT by and between PRECIGEN, INC. and THE INVESTORS PARTY HERETO Dated as of December 30, 2024 TABLE OF CONTENTS Section 1. Certain Definitions 1 Section 2. Demand Registration 4 Section 3. Piggyback Registrations 6 Section 4. S-3 Shelf Registration 8 Section 5. Suspension Periods 9 Section 6. Holdback Agreements 10 Section 7. Registration P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 Precigen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File N

Form of Performance Stock Unit Agreement under the 2023 Omnibus Incentive Plan

Form of PSU Agreement #98422604v11 PRECIGEN, INC. 2023 OMNIBUS INCENTIVE PLAN Performance Stock Unit Agreement THIS PERFORMANCE STOCK UNIT AGREEMENT (this “Agreement”) dated as of , between Precigen, Inc., a Virginia corporation (the “Company”), and (the “Participant”), is made pursuant and subject to the provisions of the Company’s 2023 Omnibus Incentive Plan, as amended (the “Plan”), a copy of w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 Precigen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File N

Precigen Reports Third Quarter 2024 Financial Results and Business Updates – Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012† in RRP

Exhibit 99.1 Precigen Reports Third Quarter 2024 Financial Results and Business Updates – Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012† in RRP under accelerated approval pathway – – Commercial and manufacturing readiness campaign underway for PRGN-2012 in anticipation of a poten

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 Precigen, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Nu

Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2024 Precigen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2024 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042 P

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates – In June 2024, the Company announced groundbreaking pivotal study data for PRGN-2012 gene therapy at the 2024 ASCO annual meeting in which more than half of R

Exhibit 99.1 Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates – In June 2024, the Company announced groundbreaking pivotal study data for PRGN-2012 gene therapy at the 2024 ASCO annual meeting in which more than half of RRP patients achieved Complete Response – – In July 2024, the Company appointed Phil Tennant as Chief Commercial Officer to spearhead pote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Precigen, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Num

Joint Filing Agreement, dated as of August 13, 2024, by and among Randal J. Kirk, the R.J. Kirk Declaration of Trust, Third Security, LLC, Sunset 2020 LLC, and Kapital Joe, LLC.

EX-99.1 2 ea021123901ex99-1precigen.htm JOINT FILING AGREEMENT, DATED AS OF AUGUST 13, 2024, BY AND AMONG RANDAL J. KIRK, THE R.J. KIRK DECLARATION OF TRUST, THIRD SECURITY, LLC, SUNSET 2020 LLC, AND KAPITAL JOE, LLC Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing

PGEN / Precigen, Inc. / KIRK RANDAL J - AMENDMENT NO. 18 TO SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 PRECIGEN, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numb

Underwriting Agreement, dated August 7, 2024, between Precigen, Inc. and Stifel, Nicolaus & Company, Incorporated.

Exhibit 1.1 PRECIGEN, INC. 35,294,118 Shares of Common Stock Underwriting Agreement August 7, 2024 Stifel, Nicolaus & Company, Incorporated as Representative of the several Underwriters listed in Schedule 1 hereto c/o Stifel, Nicolaus & Company, Incorporated One South Street, 15th Floor Baltimore, Maryland 21202 Ladies and Gentlemen: Precigen, Inc., a Virginia corporation (the “Company”), proposes

35,294,118 Shares of Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-276337 PROSPECTUS SUPPLEMENT (To Prospectus dated January 17, 2024) 35,294,118 Shares of Common Stock We are offering 35,294,118 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “PGEN”. On August 7, 2024, the last reported sale price of our common stock on the Nasdaq

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Exhibit 99.2 Precigen Announces Proposed $30 Million Public Offering of Common Stock GERMANTOWN, MD, August 6, 2024 - Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced a $30.0 million underwritten public offering of its common stock. In addition, Precigen intends to grant the underwriters a 30-day option to purchase up to an additional $4.5 million of common stock. The offering is sub

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch – PRG-2012 is on track for a rolling BLA submission under an accelerated approval pathway; patient enrollment initiated in the confirmatory clinical trial –

Exhibit 99.1 Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch – PRG-2012 is on track for a rolling BLA submission under an accelerated approval pathway; patient enrollment initiated in the confirmatory clinical trial – GERMANTOWN, MD, August 6, 2024 – Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative

SUBJECT TO COMPLETION DATED AUGUST 6, 2024

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2024 Precigen, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2024 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

Precigen Reports First Quarter 2024 Financial Results and Business Updates – Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-bre

Exhibit 99.1 Precigen Reports First Quarter 2024 Financial Results and Business Updates – Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presentation on June 3rd – – Company to host a conference call on June 3rd following the PRGN-2012 ASCO presentation to discus

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Number

Joint Filing Agreement, dated as of May 3, 2024, by and among Randal J. Kirk, the R.J. Kirk Declaration of Trust, Third Security, LLC, Sunset 2020 LLC, and Kapital Joe, LLC.

EX-99.1 2 ea020522301ex99-1precigen.htm JOINT FILING AGREEMENT, DATED AS OF MAY 3, 2024, BY AND AMONG RANDAL J. KIRK, THE R.J. KIRK DECLARATION OF TRUST, THIRD SECURITY, LLC, SUNSET 2020 LLC, AND KAPITAL JOE, LLC Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on b

PGEN / Precigen, Inc. / KIRK RANDAL J - AMENDMENT NO. 17 TO SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-36042 PREC

Precigen Reports Full Year 2023 Financial Results and Business Updates

Exhibit 99.1 Precigen Reports Full Year 2023 Financial Results and Business Updates – Significant progress made in the development of the PRGN-2012 AdenoVerse immunotherapy for the treatment of RRP; Precigen plans to submit a BLA under an accelerated approval pathway in the second half of 2024;ramping up commercial readiness activities for a potential launch in 2025 – – Precigen’s PRGN-2012 receiv

List of Subsidiaries of Precigen, Inc.

Exhibit 21.1 List of Subsidiaries of Precigen, Inc. Domestic Exemplar Genetics, LLC Iowa Precigen ActoBio, Inc. Delaware Precigen ActoBio Holdings, Inc. Delaware International ActoBio Laboratories Belgium BVBA (besloten vennootschap met beperkte aansprakelijkheid) Belgium Intrexon ActoBiotics NV (naamloze vennootschap) Belgium

Form of Restricted Stock Unit Agreement under the 2023 Omnibus Incentive Plan

1 PRECIGEN, INC. AMENDED AND RESTATED 2023 OMNIBUS INCENTIVE PLAN, AS AMENDED Restricted Stock Unit Agreement THIS RESTRICTED STOCK UNIT AGREEMENT (this “Agreement”) dated as of AGREEMENT DATE, between Precigen, Inc., a Virginia corporation (the “Company”), and FULL NAME (the “Participant”), is made pursuant and subject to the provisions of the Company’s Amended and Restated 2023 Omnibus Incentive

Precigen, Inc. Financial Statement Compensation Recoupment Policy

Confidential PRECIGEN, INC. FINANCIAL STATEMENT COMPENSATION RECOUPMENT POLICY This Precigen, Inc. Financial Statement Compensation Recoupment Policy (the “Policy”) has been adopted by the Board of Directors (the “Board”) of Precigen, Inc. (the “Company”) on June 8, 2023. This Policy provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting f

Form of Continuing Employment Agreement

Privileged and Confidential 1 \\NORTHVA - 035885/000004 - 1092466 v5 Continuing Employment Agreement This Continuing Employment Agreement (this “Agreement”) is made as of xxxxxx x, 2024 between Precigen, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36042 PRECI

Form of Incentive Stock Option Agreement under the 2023 Omnibus Incentive Plan

1 PRECIGEN, INC. 2023 OMNIBUS INCENTIVE PLAN Incentive Stock Option Agreement No. of shares subject to Incentive Stock Option: # of stock options THIS INCENTIVE STOCK OPTION AGREEMENT (this “Agreement”) dated as of the date of agreement, between Precigen, Inc., a Virginia corporation (the “Company”), and Employee Name (the “Participant”), is made pursuant and subject to the provisions of the Compa

PGEN / Precigen, Inc. / Patient Capital Management, LLC - PATIENT CAPITAL MANAGEMENT, LLC Passive Investment

SC 13G/A 1 pgena122724.htm PATIENT CAPITAL MANAGEMENT, LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* PRECIGEN, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 74017N105 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriat

PGEN / Precigen, Inc. / Ares Trading S.A. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 5)* Precigen, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46122T102 (CUSIP Number) 31 December 2023 (Date of Event Which R

Exhibit 99.1 Joint Filing Agreement, dated January 26, 2023, by and between Ares Trading SA, Merck Serono SA, Coinsins, Switzerland, Merck KGaA, Darmstadt, Germany and E.Merck KG, Darmstadt, Germany.

EX-99.1 2 tm246283d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) of the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the joint filing on behalf of each of them of the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the share capital of Precigen, Inc. This Joint Filing Agreement may be e

PGEN / Precigen, Inc. / Patient Capital Management, LLC - PATIENT CAPITAL MANAGEMENT, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 PRECIGEN, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 74017N105 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule

POWER OF ATTORNEY

EX-99.2 3 tm246283d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 POWER OF ATTORNEY E. Merck KG, Darmstadt, Germany (the “Company”), hereby makes, constitutes and appoints each of Dr. Matthias Mülllenbeck, MBA, Jens Eckhardt, Kristin Eibisch and Johannes Eckhardt, or any of them acting singly, and with full power of substitution and re-substitution, the Company’s true and lawful attorney-in-fact (each of s

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Nu

January 12, 2024

January 12, 2024 VIA EDGAR TRANSMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Cindy Polynice Re: Precigen, Inc. Registration Statement on Form S-3 Registration No. 333-276337 Dear Ms. Polynice: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effecti

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

Exhibit 99.1 Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference – PRGN-2012 Phase 2 pivotal study data in RRP is anticipated in the second quarter of 2024; the Company plans to submit a BLA under an accelerated approval pathway in the second half of 2024; commercial readiness preparations are underway for a potential launch in 2025 – – Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 PRECIGEN, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Num

Form of Indenture.

Exhibit 4.3 INDENTURE DATED AS OF , 20 BETWEEN PRECIGEN, INC. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 6 Section 1.03 Form of Documents Delivered to Trustee 6 Section 1.04 Acts of Holders; Recor

Filing fee table.

Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Precigen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward

Specimen certificate evidencing shares of common stock.

Exhibit 4.1 [FACE OF CERTIFICATE] PI PRECIGEN, INC. SHARES COMMON STOCK SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 74017N 10 5 INCORPORATED UNDER THE LAWS OF THE STATE OF VIRGINIA THIS CERTIFIES THAT: is the owner of FULLY PAID AND NONASSESSABLE SHARES OF THE COMMON STOCK, NO PAR VALUE, OF Precigen, Inc. transferable on the books of the Corporation in person or by duly authorized attorney upon surr

As filed with the Securities and Exchange Commission on December 29, 2023

As filed with the Securities and Exchange Commission on December 29, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36

Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

Exhibit 99.1 Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs – Based on FDA confirmation in August 2023 that the ongoing Phase 1/2 single-arm study of PRGN-2012 in RRP will serve as the pivotal study to support BLA submission under an accelerated approval request, the Company has expedited efforts to attain commercial readiness – – Full results of the Phase

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Nu

Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025

Exhibit 99.1 Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025 – The FDA confirmed that the ongoing Phase 1/2 single arm study of PRGN-2012 in RRP will serve as the pivotal study to support accelerated approval and no additional randomized, placebo-control

Amended and Restated Exclusive License Agreement with Alaunos Therapeutics, dated April 3, 2023.

pgen-20230630x10qxexx101 1. #96844255v2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Omissions are designated as [*****]. AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT This AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is entere

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 Precigen, Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numb

Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

Exhibit 99.2 Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval – FDA confirmed that the ongoing Phase 1/2 single arm study will serve as pivotal and no additional randomized, placebo-controlled trial will be required to support submission of a BLA – – FDA agreed on the required

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042 P

As filed with the Securities and Exchange Commission on July 6, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Precigen, Inc. (Exact name of registrant as specifie

As filed with the Securities and Exchange Commission on July 6, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Precigen, Inc.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Precigen, Inc. 2023 Omnibus Incentive Plan (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2)(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equity Commo

Precigen, Inc. 2023 Omnibus Incentive Plan

Exhibit 99.1 Precigen, Inc. 2023 OMNIBUS INCENTIVE PLAN Section 1. Purpose. The purpose of the Precigen, Inc. 2023 Omnibus Incentive Plan (as amended from time to time, the “Plan”) is to motivate and reward employees and other individuals to perform at the highest level and contribute significantly to the success of Precigen, Inc. (the “Company”), thereby furthering the best interests of the Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 Precigen, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Number

Precigen Reports First Quarter 2023 Financial Results and Business Updates – Positive Phase 1 clinical data presented for PRGN-2012 AdenoVerse™ immunotherapy in RRP demonstrated favorable safety profile and significant reduction in surgeries with 50%

Exhibit 99.1 Precigen Reports First Quarter 2023 Financial Results and Business Updates – Positive Phase 1 clinical data presented for PRGN-2012 AdenoVerse™ immunotherapy in RRP demonstrated favorable safety profile and significant reduction in surgeries with 50% of the patients in Complete Response following treatment with PRGN-2012 – – Enrollment completed in the Phase 2 study of PRGN-2012 in RR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Precigen, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042

Amended and Restated Exclusive License Agreement with Alaunos Therapeutics, dated April 3, 2023.

pgen-20230331x10qxexx101 1. #96844255v2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Omissions are designated as [*****]. AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT This AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is entere

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ___)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 Precigen, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numbe

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numb

Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Exhibit 99.1 Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates – Achieved significant clinical progress for UltraCAR-T® and AdenoVerse™ investigational therapeutics in 2022 – – Presented positive clinical data for PRGN-2012 AdenoVerse immunotherapy in recurrent respiratory papillomatosis (RRP) showing favorable safety profile and significant reduction in sur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36042 PRECI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 Precigen, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numbe

List of Subsidiaries of Precigen, Inc.

Exhibit 21.1 List of Subsidiaries of Precigen, Inc. Domestic Exemplar Genetics, LLC Iowa PGEN Therapeutics, Inc. Delaware Precigen ActoBio, Inc. Delaware Precigen ActoBio Holdings, Inc. Delaware International ActoBio Laboratories Belgium BVBA (besloten vennootschap met beperkte aansprakelijkheid) Belgium Intrexon ActoBiotics NV (naamloze vennootschap) Belgium

PGEN / Precigen Inc / KIRK RANDAL J - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.

Joint Filing Agreement

Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Precigen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 PRECIGEN, INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Nu

POWER OF ATTORNEY

EX-99.2 3 tm234513d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 POWER OF ATTORNEY E. Merck KG, Darmstadt, Germany (the “Company”), hereby makes, constitutes and appoints each of Dr. Matthias Mülllenbeck, MBA, Jens Eckhardt, Kristin Eibisch and Johannes Eckhardt, or any of them acting singly, and with full power of substitution and re-substitution, the Company’s true and lawful attorney-in-fact (each of s

JOINT FILING AGREEMENT

EX-99.1 2 tm234513d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) of the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the joint filing on behalf of each of them of the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the share capital of Precigen, Inc. This Joint Filing Agreement may be e

Underwriting Agreement, dated January 24, 2023, between Precigen, Inc. and the Underwriters named therein.

Exhibit 1.1 PRECIGEN, INC. 42,857,143 Shares of Common Stock Underwriting Agreement January 24, 2023 J.P. Morgan Securities LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Precigen, Inc., a Virginia corporation (the “Company”), proposes to issue and sell to the several und

PGEN / Precigen Inc / Ares Trading S.A. - SC 13G/A Passive Investment

SC 13G/A 1 tm234513d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 4)* Precigen, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46122T102 (CUSIP Number

Book-Running Managers

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-239366 PROSPECTUS SUPPLEMENT (To Prospectus dated July 2, 2020) 42,857,143 Shares Common Stock We are offering 42,857,143 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “PGEN.” On January 24, 2023, the last reported sale price of our common stock on the Nasdaq Globa

Book-Running Managers

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Nu

Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis – Repeated administrations of PRGN-2012 were wel

Exhibit 99.1 Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis – Repeated administrations of PRGN-2012 were well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2 – – Clinical data show strong r

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Nu

Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference – Company achieved significant progress for its clinical pipeline in 2022 – – Precigen to host R&D Day virtual event on January 24, 2023, at 4:30 PM

Exhibit 99.1 Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference – Company achieved significant progress for its clinical pipeline in 2022 – – Precigen to host R&D Day virtual event on January 24, 2023, at 4:30 PM ET to share safety and efficacy data from the Phase 1 dose escalation and expansion cohorts of PRGN-2012 AdenoVerse™ immunotherapy in re

Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs – Company will host virtual R&D event in early January 2023, timed to coincide with the 41st Annual JP Morgan Healthcare Conference, to showcase complete clinical

Exhibit 99.1 Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs – Company will host virtual R&D event in early January 2023, timed to coincide with the 41st Annual JP Morgan Healthcare Conference, to showcase complete clinical trial data from Phase 1 dose escalation and expansion cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in recurrent respiratory papillomat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 Precigen, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Nu

Exhibit 1

Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Precigen, Inc.

PGEN / Precigen Inc / KIRK RANDAL J - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File

Precigen Names Rutul R. Shah Chief Operating Officer

Exhibit 99.1 Precigen Names Rutul R. Shah Chief Operating Officer GERMANTOWN, MD, September 21, 2022 ? Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today named Rutul R. Shah as the Company?s Chief Operating Officer (COO), effective October 1, 2022. Mr. Shah has been with the Compan

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2022 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation)

Precigen, Inc. Unaudited Pro Forma Condensed Consolidated Balance Sheet As of June 30, 2022

Exhibit 99.1 Unaudited Pro Forma Condensed Consolidated Financial Information Effective as of August 18, 2022, Precigen, Inc., a Virginia corporation (the ?Company?), and its wholly-owned subsidiary, Trans Ova Genetics, L.C., an Iowa limited liability company (?Trans Ova?), completed the previously announced sale of 100% of the issued and outstanding membership interests of Trans Ova to Spring Bid

Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics

Exhibit 99.1 Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics August 22, 2022 ? Proceeds include $170 million in upfront cash and up to $10 million earn-out over two years ? GERMANTOWN, Md., Aug. 22, 2022 /PRNewswire/ - Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of pati

Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2022 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Num

Sales Agreement, dated August 9, 2022, between Precigen, Inc. and Cantor Fitzgerald & Co.

Exhibit 1.1 EXECUTION VERSION Precigen, Inc. Shares of Common Stock (no par value per share) Controlled Equity OfferingSM Sales Agreement August 9, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Precigen, Inc., a Virginia corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), as follows: 1. Issuance

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numb

UP TO $100,000,000 SHARES OF COMMON STOCK

Filed Pursuant to Rule 424(b)(5) Registration No. 333-239366 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 2, 2020) UP TO $100,000,000 SHARES OF COMMON STOCK We have entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to shares of our common stock, no par value per share, offered by this prospectus suppleme

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042 P

Precigen Reports Second Quarter and First Half 2022 Financial Results

Exhibit 99.1 Precigen Reports Second Quarter and First Half 2022 Financial Results ? Enrollment complete in Phase 1 study of PRGN-3006 UltraCAR-T?? in acute myeloid leukemia (AML); enrollment ongoing in Phase 1b dose expansion study; Mayo Clinic in Rochester, Minnesota activated as first expansion site of Phase 1b multicenter expansion; technology transfer and site activation activities underway a

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2022 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numbe

Membership Interest Purchase Agreement dated July 1, 2022 by and among Precigen, Inc., Trans Ova Genetics, L.C. and Spring Bidco LLC, originally filed as Exhibit 2.1 to Precigen’s Form 8-K filed with the SEC on July 5, 2022, which is incorporated by reference herein

Exhibit 2.1 MEMBERSHIP INTEREST PURCHASE AGREEMENT BY AND AMONG PRECIGEN, INC., TRANS OVA GENETICS, L.C. AND SPRING BIDCO LLC Dated as of July 1, 2022 Table of Contents Article I Definitions and Terms 1 Section 1.01 Defined Terms. 1 Section 1.02 Interpretation Provisions. 16 Article II Purchase and Sale 17 Section 2.01 Purchase and Sale of Membership Interests. 17 Section 2.02 Purchase Price. 17 S

Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics

Exhibit 99.1 Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics July 5, 2022 ? Precigen enters into agreement to sell wholly-owned subsidiary Trans Ova Genetics to URUS for $170 million in upfront cash and up to $10 million earn-out over two years; close expected in Q3 2022 ? ? Transaction, upon closing, will solidify balance sheet and the Company intends to pay

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2022 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Number

Guarantee by and among Precigen, Inc., Trans Ova Genetics, L.C., Spring Bidco LLC and Houdstermaatschappij Wilg B.V., dated as of July 1, 2022, originally filed as Exhibit 2.2 to Precigen’s Form 8-K filed with the SEC on July 5, 2022, which is incorporated by reference herein

Exhibit 2.2 GUARANTEE This guarantee (this ?Agreement?) is entered into as of July 1, 2022, by and among PRECIGEN, INC., a Virginia corporation (?Seller?), TRANS OVA GENETICS, L.C., an Iowa limited liability company (the ?Company?), Spring Bidco LLC, a Delaware limited liability company (?Buyer?) and Houdstermaatschappij Wilg B.V. (?Guarantor?). Buyer, the Company and Seller are each referred to h

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Number

Precigen Reports First Quarter 2022 Financial Results and Business Updates – Fast Track designation received for PRGN-3006 UltraCAR-T®, an important milestone for patients with relapsed or refractory acute myeloid leukemia, a rapidly progressing dise

Exhibit 99.1 Precigen Reports First Quarter 2022 Financial Results and Business Updates ? Fast Track designation received for PRGN-3006 UltraCAR-T?, an important milestone for patients with relapsed or refractory acute myeloid leukemia, a rapidly progressing disease with limited treatment options ? ? Phase 1b expansion arm initiated for PRGN-3006 UltraCAR-T? at Dose Level 3 with lymphodepletion ?

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ___)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ___)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Precigen Reports Fourth Quarter and Full Year 2021 Financial Results – 2021 clinical milestone objectives successfully accomplished – – Positive clinical data presented across three platforms – UltraCAR-T®, AdenoVerseTM, ActoBioticsTM – and five clin

Exhibit 99.1 Precigen Reports Fourth Quarter and Full Year 2021 Financial Results ? 2021 clinical milestone objectives successfully accomplished ? ? Positive clinical data presented across three platforms ? UltraCAR-T?, AdenoVerseTM, ActoBioticsTM ? and five clinical programs ? ? Public offering to strengthen balance sheet successfully closed while streamlining operations and reducing operating ex

List of Subsidiaries of Precigen, Inc.

Exhibit 21.1 List of Subsidiaries of Precigen, Inc. Domestic Exemplar Genetics, LLC Iowa PGEN Therapeutics, Inc. Delaware Precigen ActoBio, Inc. Delaware Precigen ActoBio Holdings, Inc. Delaware Trans Ova Genetics, L.C. Iowa International ActoBio Laboratories Belgium BVBA (besloten vennootschap met beperkte aansprakelijkheid) Belgium Intrexon ActoBiotics NV (naamloze vennootschap) Belgium

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36042 PRECI

PGEN / Precigen Inc / Ares Trading S.A. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 3)* Precigen, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46122T102 (CUSIP Number) 31 December 2021 (Date of Event Which R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Nu

Precigen Achieves Significant Clinical Progress for UltraCAR-T® and AdenoVerse™ Therapies – 50% (3 out of 6) objective response rate (ORR) in relapsed or refractory (r/r) acute myeloid leukemia (AML) patients treated with PRGN-3006 at the two lowest

EXHIBIT 99.1 Precigen Achieves Significant Clinical Progress for UltraCAR-T? and AdenoVerse? Therapies ? 50% (3 out of 6) objective response rate (ORR) in relapsed or refractory (r/r) acute myeloid leukemia (AML) patients treated with PRGN-3006 at the two lowest dose levels (a single administration of 4 to 28 million UltraCAR-T cells) in the lymphodepletion cohort of the ongoing Phase 1 trial ? ?

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2021 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Nu

Precigen Appoints Harry Thomasian Jr. as Chief Financial Officer

Exhibit 99.1 Precigen Appoints Harry Thomasian Jr. as Chief Financial Officer GERMANTOWN, MD, October 12, 2021 ? Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Harry Thomasian Jr. as the Company?s chief financial officer (CFO), effective October 18,

Precigen Reports Second Quarter and First Half 2021 Financial Results

Exhibit 99.1 Precigen Reports Second Quarter and First Half 2021 Financial Results - Company to provide comprehensive clinical pipeline and data updates at R&D call on November 4th - GERMANTOWN, MD, August 9, 2021 ? Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced secon

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042 P

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numb

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numbe

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2021 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Number

Precigen Reports First Quarter 2021 Financial Results – Company on track to achieve stated 2021 milestones – – Initiated Phase 2 clinical trial of PRGN-2009 AdenoVerse™ immunotherapy – – Initiated Phase 1 clinical trial of PRGN-2012 AdenoVerse immuno

Exhibit 99.1 Precigen Reports First Quarter 2021 Financial Results ? Company on track to achieve stated 2021 milestones ? ? Initiated Phase 2 clinical trial of PRGN-2009 AdenoVerse? immunotherapy ? ? Initiated Phase 1 clinical trial of PRGN-2012 AdenoVerse immunotherapy in patients with recurrent respiratory papillomatosis (RRP) ? ? Upcoming presentation at FOCIS Virtual Annual Meeting to provide

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Number

- FORM DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

- FORM DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

- FORM DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

Precigen Announces Departure of Chief Financial Officer - Commences search for new CFO -

Exhibit 99.1 Precigen Announces Departure of Chief Financial Officer - Commences search for new CFO - Germantown, Maryland, March 30, 2021 – Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that by mutual agreement Rick Sterling is stepping down from his position as Chief Financial Of

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2021 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numb

List of Subsidiaries of Precigen, Inc.

Exhibit 21.1 List of Subsidiaries of Precigen, Inc. Domestic Exemplar Genetics, LLC Iowa Genomatix, Inc. Delaware GenVec LLC Delaware Intrexon AB, Co. Delaware Intrexon CEU, Inc. Delaware Intrexon Energy Partners, LLC Delaware Intrexon Energy Partners II, LLC Delaware MabLogix, LLC Delaware MBP Titan LLC Delaware PGEN Therapeutics, Inc. Delaware Precigen ActoBio, Inc. Delaware Precigen ActoBio CED

Precigen Reports Fourth Quarter and Full Year 2020 Financial Results – Company successfully accomplished anticipated 2020 clinical milestones despite challenges due to the ongoing pandemic – – Strengthened balance sheet with successful public offerin

EX-99.1 Exhibit 99.1 Precigen Reports Fourth Quarter and Full Year 2020 Financial Results – Company successfully accomplished anticipated 2020 clinical milestones despite challenges due to the ongoing pandemic – – Strengthened balance sheet with successful public offering while streamlining operations and reducing operating costs – – Initial data readouts from PRGN-3005 and PRGN-3006 UltraCAR-T® c

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numbe

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36042 PRECI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Precigen, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74017N105 (CUSIP Number) Dec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Precigen, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74017N105 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2021 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Nu

Underwriting Agreement, dated January 21, 2021, between Precigen, Inc. and the Underwriters named therein.

EX-1.1 Exhibit 1.1 Execution version PRECIGEN, INC. 15,000,000 Shares of Common Stock Underwriting Agreement January 21, 2021 Wells Fargo Securities, LLC Stifel, Nicolaus & Company, Incorporated As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Wells Fargo Securities, LLC 500 West 33rd Street New York, New York 10001 c/o Stifel, Nicolaus & Company, Incorporated One Sou

15,000,000 Shares Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-239366 PROSPECTUS SUPPLEMENT (To Prospectus dated July 2, 2020) 15,000,000 Shares Common Stock We are offering 15,000,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “PGEN.” On January 21, 2021, the last reported sale price of our common stock on the Nasdaq G

SUBJECT TO COMPLETION, JANUARY 21, 2021

424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed.

Regulation FD Disclosure, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2021 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Nu

Forward-looking Statements Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based

EX-99.1 39th Annual J.P. Morgan Healthcare Conference 13 January 2021 Helen Sabzevari, PhD President & CEO EXHIBIT 99.1 Forward-looking Statements Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon Precigen's current expec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendmen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Precigen, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46122T102 (CUSIP Number) 31 December 2020 (Date of Event Which R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No. 14)* Under the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.

Exhibit 1

Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Precigen, Inc.

Unregistered Sales of Equity Securities - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2020 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Nu

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Nu

INTERNAL & CONFIDENTIAL Precigen Reports Third Quarter 2020 and Year-to-Date Financial Results – Company to provide comprehensive clinical pipeline and data updates in early December – – Continues to advance healthcare portfolio and improve fiscal pe

EX-99.1 Exhibit 99.1 INTERNAL & CONFIDENTIAL Precigen Reports Third Quarter 2020 and Year-to-Date Financial Results – Company to provide comprehensive clinical pipeline and data updates in early December – – Continues to advance healthcare portfolio and improve fiscal performance by executing operational efficiencies – – Company to present PRGN-3006 UltraCAR-T at ASH annual meeting on December 7th

Executive Chairman Compensation Arrangement, by and between the Company and Randal J. Kirk

Exhibit 10.1 EXECUTIVE CHAIRMAN COMPENSATION ARRANGEMENT The following is a description of the compensation arrangement for Randal J. Kirk, Precigen, Inc.’s (“Precigen”) Executive Chairman (the “Compensation Arrangement”). The Compensation Arrangement is not set forth in a formal written document, and therefore Precigen is providing this description pursuant to Item 601(b)(10)(iii) of Regulation S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36

Precigen Announces Merck KGaA, Darmstadt, Germany Increases Ownership Position Through Exercise of Convertible Note

EX-99.1 Exhibit 99.1 Precigen Announces Merck KGaA, Darmstadt, Germany Increases Ownership Position Through Exercise of Convertible Note GERMANTOWN, MD, October 9, 2020 - Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that leading science and technology company and ex

Regulation FD Disclosure, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2020 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Num

-

CORRESP Precigen, Inc. 20374 Seneca Meadows Parkway Germantown, Maryland 20876 October 7, 2020 VIA EDGAR U.S. Securities and Exchange Commission Office of Trade and Services Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Precigen, Inc. Registration Statement on Form S-3 File No. 333-249172 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 of the Gen

LETTER

United States securities and exchange commission logo October 2, 2020 Helen Sabzevari Chief Executive Officer Precigen, Inc.

-

United States securities and exchange commission logo October 2, 2020 Helen Sabzevari Chief Executive Officer Precigen, Inc.

- S-3

S-3 As filed with the Securities and Exchange Commission on September 30, 2020 Registration No.

Power of Attorney.

EX-24.1 Exhibit 24.1 PRECIGEN, INC. POWER OF ATTORNEY The undersigned officers and directors of Precigen, Inc., a Virginia corporation (the “Company”), hereby constitute and appoint Helen Sabzevari, Donald P. Lehr, and Rick L. Sterling, and each of them, the true and lawful agents and attorneys-in-fact of the undersigned with full power and authority in said agents and attorneys-in-fact, and each

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2020 PRECIGEN, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2020 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2020 PRECIGEN, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2020 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Num

Event Name: Precigen Second Quarter 2020 Financial Results Conference Call

EX-99.1 Exhibit 99.1 Event Name: Precigen Second Quarter 2020 Financial Results Conference Call Event Date: Monday, August 10, 2020, 4:30 PM Eastern Time Presenters Steven Harasym; Precigen, Inc.; Head of Investor Relations Helen Sabzevari; Precigen, Inc.; President and Chief Executive Officer Tom Samuelson; Precigen, Inc.; Head of Financial Strategy Analysts Roy Buchanan, JMP Securities Presentat

Exhibit 1

Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Precigen, Inc.

PGEN / Precigen, Inc. / KIRK RANDAL J - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.

Q2 2020 Financial Highlights Improvement in quarter over quarter Segment Adjusted EBITDA Reduction in capital requirements driven by suspension of MBP Titan operations and streamlining corporate functions Trans Ova Genetics and Precigen Exemplar cash

EX-99.2 Exhibit 99.2 Precigen, Inc. 2Q-2020 Business Update 10 August 2020 1Exhibit 99.2 Precigen, Inc. 2Q-2020 Business Update 10 August 2020 1 Forward-looking Statements Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon

Reconciliation of Segment Adjusted EBITDA for Reportable Segments to Consolidated Net Loss from Continuing Operations Before Income Taxes The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continu

EX-99.3 Non-GAAP Financial Information This presentation includes Segment Adjusted EBITDA, which is a non-GAAP financial measure within the meaning of applicable rules and regulations of the Securities and Exchange Commission (SEC). Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underl

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042 P

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Num

Precigen Reports Second Quarter and First Half 2020 Financial Results – Announced proprietary electroporation device, UltraPorator™, designed to scale-up UltraCAR-T® manufacturing at multiple medical centers – – Announced positive topline results fro

EX-99.1 2 d37132dex991.htm EX-99.1 Exhibit 99.1 Precigen Reports Second Quarter and First Half 2020 Financial Results – Announced proprietary electroporation device, UltraPorator™, designed to scale-up UltraCAR-T® manufacturing at multiple medical centers – – Announced positive topline results from Phase 1b study of AG019 ActoBiotics™ for type 1 diabetes – – Met primary endpoints of safety and fea

-

United States securities and exchange commission logo June 30, 2020 Helen Sabzevari President and Chief Executive Officer Precigen, Inc.

LETTER

United States securities and exchange commission logo June 30, 2020 Helen Sabzevari President and Chief Executive Officer Precigen, Inc.

-

CORRESP Precigen, Inc. 20374 Seneca Meadows Parkway Germantown, Maryland 20876 June 30, 2020 VIA EDGAR U.S. Securities and Exchange Commission Office of Trade and Services Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Precigen, Inc. Registration Statement on Form S-3 File No. 333-239366 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 of the Gener

Specimen certificate evidencing shares of common stock.

EX-4.1 Exhibit 4.1 [FACE OF CERTIFICATE] PI PRECIGEN, INC. SHARES COMMON STOCK SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 74017N 10 5 INCORPORATED UNDER THE LAWS OF THE STATE OF VIRGINIA THIS CERTIFIES THAT: is the owner of FULLY PAID AND NONASSESSABLE SHARES OF THE COMMON STOCK, NO PAR VALUE, OF Precigen, Inc. transferable on the books of the Corporation in person or by duly authorized attorney up

Power of Attorney.

EX-24.1 Exhibit 24.1 PRECIGEN, INC. POWER OF ATTORNEY The undersigned officers and directors of Precigen, Inc., a Virginia corporation (the “Company”), hereby constitute and appoint Helen Sabzevari, Donald P. Lehr, and Rick L. Sterling, and each of them, the true and lawful agents and attorneys-in-fact of the undersigned with full power and authority in said agents and attorneys-in-fact, and each

- S-8

S-8 As filed with the Securities and Exchange Commission on June 22, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Precigen, Inc.

Powers of Attorney.

EX-24.1 Exhibit 24.1 PRECIGEN, INC. POWER OF ATTORNEY The undersigned officers and directors of Precigen, Inc., a Virginia corporation (the “Company”), hereby constitute and appoint Helen Sabzevari, Donald P. Lehr, and Rick L. Sterling, and each of them, the true and lawful agents and attorneys-in-fact of the undersigned with full power and authority in said agents and attorneys-in-fact, and each

Risk Factors

S-3 Table of Contents As filed with the Securities and Exchange Commission on June 22, 2020 Registration No.

Form of Indenture.

EX-4.3 3 d933596dex43.htm EX-4.3 Exhibit 4.3 INDENTURE DATED AS OF , 20 BETWEEN PRECIGEN, INC. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 6 Section 1.03 Form of Documents Delivered to Trustee 6 Se

Specimen certificate evidencing shares of common stock

EX-4.1 2 d933596dex41.htm EX-4.1 Exhibit 4.1 [FACE OF CERTIFICATE] PI PRECIGEN, INC. SHARES COMMON STOCK SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 74017N 10 5 INCORPORATED UNDER THE LAWS OF THE STATE OF VIRGINIA THIS CERTIFIES THAT: is the owner of FULLY PAID AND NONASSESSABLE SHARES OF THE COMMON STOCK, NO PAR VALUE, OF Precigen, Inc. transferable on the books of the Corporation in person or by d

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2020 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numbe

Amendment to the Amended and Restated 2013 Omnibus Incentive Plan of the Company, as amended, effective as of June 19, 2020

EX-10.1 Exhibit 10.1 Amendment to the Precigen, Inc. Amended and Restated 2013 Omnibus Incentive Plan, as Amended The first paragraph of Section 6.02 of the Precigen, Inc. Amended and Restated 2013 Omnibus Incentive Plan is amended to read as follows: “6.02 Aggregate Limit The maximum aggregate number (the “Maximum Aggregate Number”) of shares of Common Stock which may be subject to Awards under t

Amended and Restated Bylaws

EX-3.1 EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF PRECIGEN, INC. June 3, 2020 ARTICLE I MEETINGS OF SHAREHOLDERS Section 1.1. Place of Meetings. All meetings of the shareholders of Precigen, Inc. (hereinafter called the “Corporation”) shall be held at such place, either within or without the Commonwealth of Virginia, or solely by means of remote communication, as may from time to time be determine

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2020 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Number

- DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Number)

MAY 06, 2020 / 8:15PM GMT, Q1 2020 Precigen Inc Earnings Call In the first quarter of 2020, Precigen spending, which includes segment AEBITDA plus unallocated corporate costs was approximately $30 million versus $39 million in the first quarter of 20

EX-99.1 Exhibit 99.1 MAY 06, 2020 / 8:15PM GMT, Q1 2020 Precigen Inc Earnings Call CORPORATE PARTICIPANTS Helen Sabzevari Precigen, Inc. - President & CEO Steven Harasym Precigen, Inc. - Head of Investor Relations Tom Samuelson Precigen, Inc. - Head of Financial Strategy CONFERENCE CALL PARTICIPANTS Jason Nicholas Butler JMP Securities LLC, Research Division - MD and Senior Research Analyst Swayam

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042

Amendment to the Amended and Restated 2013 Omnibus Incentive Plan of the Company, as amended, effective January 5, 2020

EX-10.1 2 pgen-20200331xexx101.htm EX 10.1 Exhibit 10.1 AMENDMENT TO THE INTREXON CORPORATION AMENDED AND RESTATED 2013 OMNIBUS INCENTIVE PLAN The Intrexon Corporation Amended and Restated 2013 Omnibus Incentive Plan, as amended (the “2013 Plan”), is hereby amended, effective as of January 5, 2020, as follows: 1. The first sentence of Section 6.03 of the 2013 Plan is hereby deleted and replaced in

Reconciliation of Segment Adjusted EBITDA for Reportable Segments to Consolidated Net Loss from Continuing Operations Before Income Taxes The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continu

EX-99.3 4 d890406dex993.htm EX-99.3 Non-GAAP Financial Information This presentation includes Segment Adjusted EBITDA, which is a non-GAAP financial measure within the meaning of applicable rules and regulations of the Securities and Exchange Commission (SEC). Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are

Precigen Reports First Quarter 2020 Financial Results – Achieves significant progress in streamlining healthcare operations and reducing operating costs – – Maintains guidance for clinical readouts in 2020 – – Completes reduction in force at MBP Tita

EX-99.1 2 d890406dex991.htm EX-99.1 Exhibit 99.1 Precigen Reports First Quarter 2020 Financial Results – Achieves significant progress in streamlining healthcare operations and reducing operating costs – – Maintains guidance for clinical readouts in 2020 – – Completes reduction in force at MBP Titan to focus resources on healthcare – – Received FDA clearance of PRGN-2009 to initiate a Phase 1/2 tr

Adhering to Operating Principles to Deliver Value to All Stakeholders PRECIGEN’S VISION FOR PATIENTS Develop life-saving and cost-conscious therapies utilizing our cutting-edge platform technologies for patients with unmet need FISCAL STRENGTH Respon

EX-99.2 Precigen, Inc. 1Q-2020 Business Update 6 May 2020 Exhibit 99.2 Forward-looking Statements Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon Precigen's current expectations and projections about future events and g

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Number)

April 29, 2020

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

- DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042 PRECI

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2020 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Numbe

Precigen Reports Fourth Quarter and Year End 2019 Financial Results – Company completed series of transactions to support tighter focus on healthcare – – Quarterly GAAP revenues from continuing operations of $17.0 million and net loss attributable to

EX-99.1 Exhibit 99.1 Precigen Reports Fourth Quarter and Year End 2019 Financial Results – Company completed series of transactions to support tighter focus on healthcare – – Quarterly GAAP revenues from continuing operations of $17.0 million and net loss attributable to Precigen of $169.2 million, of which $95.7 million was from discontinued operations and an additional $33.8 million was for non-

Exhibit 4.5

Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of Precigen, Inc. (“we” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended is our common stock, no par value. DESCRIPTI

Forward-looking Statements Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based

EX-99.2 Precigen 4Q-2019 Business Update 2 March 2020 Exhibit 99.2 Forward-looking Statements Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon Precigen's current expectations and projections about future events and gener

List of Subsidiaries of Precigen, Inc.

Exhibit 21.1 List of Subsidiaries of Precigen, Inc. Domestic Exemplar Genetics, LLC Iowa Genomatix, Inc. Delaware GenVec LLC Delaware Intrexon AB, Co. Delaware Intrexon CEU, Inc. Delaware Intrexon EF Holdings, Inc. Delaware Intrexon Energy Partners, LLC Delaware Intrexon Energy Partners II, LLC Delaware MabLogix, LLC Delaware MBP Titan LLC Delaware PGEN Therapeutics, Inc. Delaware Precigen ActoBio

XON / Intrexon Corp. / LMM LLC - MILLER VALUE PARTNERS, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Intrexon Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 46122T102 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2020 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Nu

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2020 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation)

PRECIGEN, INC. UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS

EX-99.1 2 d860631dex991.htm EX-99.1 Exhibit 99.1 PRECIGEN, INC. UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS On January 31, 2020, Precigen, Inc., formerly known as Intrexon Corporation, (“the Company”) and TS Biotechnology Holdings, LLC (“TS Biotechnology”), a Virginia limited liability company managed by Third Security, LLC (“Third Security”), completed the previously announced sale of t

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2020 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Nu

Amended and Restated Articles of Incorporation

EX-3.1 2 d876809dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION of PRECIGEN, INC. ARTICLE I The name of the Corporation shall be Precigen, Inc. ARTICLE II The purpose for which the Corporation is formed is to transact any or all lawful business, not required to be specifically stated in these Amended and Restated Articles of Incorporation, for which corporations may be

PRECIGEN COMPLETES SERIES OF TRANSACTIONS TO SOLIDIFY HEALTHCARE FOCUS - Company on Track to Advance Next-Generation Gene & Cell Therapies - - Company Name Changes to Precigen from Intrexon and Ticker Symbol to Nasdaq: PGEN -

EX-99.1 Exhibit 99.1 PRECIGEN COMPLETES SERIES OF TRANSACTIONS TO SOLIDIFY HEALTHCARE FOCUS - Company on Track to Advance Next-Generation Gene & Cell Therapies - - Company Name Changes to Precigen from Intrexon and Ticker Symbol to Nasdaq: PGEN - GERMANTOWN, Md., Feb. 3, 2020 — Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell th

XON / Intrexon Corp. / KIRK RANDAL J - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.

Exhibit 2

Exhibit 2 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Precigen, Inc.

Amended and Restated Bylaws

EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF PRECIGEN, INC. February 1, 2020 ARTICLE I MEETINGS OF SHAREHOLDERS Section 1.1. Place of Meetings. All meetings of the shareholders of Precigen, Inc. (hereinafter called the “Corporation”) shall be held at such place, either within or without the Commonwealth of Virginia, as may from time to time be fixed by the Board of Directors of the Corporatio